We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Metamark Genetics and Definiens Form Partnership to Develop Cancer Diagnostics

By LabMedica International staff writers
Posted on 07 Jul 2011
Metamark Genetics, Inc. More...
(Cambridge, MA, USA) a privately held oncology molecular diagnostic company, and Definiens (Munich, Germany) a health image-intelligence company, announced a development and commercialization partnership. The partnership combines Metamark's proprietary multiplex protein detection platform with image analysis technology developed jointly with Definiens to deliver innovative prognostic and predictive assays for early-stage cancers.

"We see great synergy in combining Definiens' technology and expertise with Metamark's unique understanding of tumor heterogeneity and insight into the molecular drivers regulating tumor formation and aggression. We believe that this partnership will enable us to codevelop and implement unique and important image analysis tools," said Eric Devroe, PhD, vice president of business & strategy development for Metamark.

Metamark's quantitative diagnostic approach can identify small regions of molecularly aggressive cancer cells within an otherwise indolent tumor. The company is addressing the "heterogeneous" nature of tumors not only between one patient and the next, but also within an individual patient's tumor by developing a portfolio of prognostic and predictive assays.

Definiens has made major achievements in the field of biomarker development based on its robust and scalable image analysis framework enabling scientists and clinicians to extract rapidly comprehensive biomarker and morphology expression profiles and to identify a relevant subset of descriptors by correlating them against patient outcomes.

"The capability to provide detailed readouts from tissue analysis is opening up new gateways for developing diagnostic assays as we enter the age of personalized medicine. We believe the Definiens Developer XD and Tissue Studio software will enable Metamark to classify tumor heterogeneity of multiplexed tissue stains and derive prognostic and predictive assays," said Thomas Colarusso, vice president of sales & operations for Definiens.

Related Links:
Metamark Genetics, Inc.
Definiens


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Platelet Function Analyzer
PL-12
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.